Full-Time

Scientist – Analytical Development

Posted on 9/10/2024

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

Biotechnology
Healthcare

Mid, Senior

Norwood, MA, USA

70% in-office structure.

Category
Bioinformatics
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • MS with 5-8 years or BS with 8-10 years of biotech or pharmaceutical industry experience in analytical development.
  • Strong background in chromatographic separation, biophysical characterization, and spectrophotometric techniques, equipment platforms (e.g. Thermo, Waters, Agilent) and data processing software (e.g. Chromeleon, ChemStation, Empower).
  • Knowledge of industry standards and current FDA and ICH guidelines.
Responsibilities
  • Work closely Analytical Program Leads to support stability study designs based on practical understanding of ICH stability guidelines
  • Develop and author stability study plans, protocols, and reports to support development of early to late phase mRNA-LNP vaccines and therapeutics programs
  • Work closely with CMC statistical team on stability data analysis and perform data trending
  • Provide technical leadership to support investigations of out of specification or out of trend analytical results in collaboration with analytical technical operations and quality organization.
  • Generate high quality documentation to support regulatory submissions and internal communications.
  • Serve as a subject matter expert in stability to support analytical development, process development, analytical science and technology, manufacturing, quality, supply chain and regulatory teams.
  • Additional duties as may be assigned from time to time

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in how cells produce proteins necessary for various biological functions. Their approach involves creating a new class of medicines that utilize mRNA to instruct cells to produce specific proteins, potentially leading to significant advancements in treating diseases. Unlike traditional pharmaceuticals, which often rely on small molecules or proteins, Moderna's mRNA-based therapies aim to enhance the speed and efficiency of drug discovery and manufacturing. The company's goal is to improve patient outcomes by harnessing the power of mRNA to create effective treatments for a range of health conditions.

Company Stage

IPO

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

2010

Growth & Insights
Headcount

6 month growth

4%

1 year growth

15%

2 year growth

48%
Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's AI-driven drug discovery accelerates novel mRNA-based therapeutics identification.
  • Expansion in Asia enhances global supply chain and reduces production costs.
  • mRNA technology is gaining traction for non-infectious disease vaccines, like cancer.

What critics are saying

  • Potential Nasdaq 100 removal could impact stock visibility and investor interest.
  • Bypassing safety steps in Australia may raise regulatory and public scrutiny concerns.
  • Hong Kong's reluctance to receive Covid-19 jab affects market penetration and sales.

What makes Moderna unique

  • Moderna is pioneering mRNA technology for a new class of medicines.
  • The company focuses on mRNA's potential to transform drug discovery and manufacturing.
  • Moderna's mRNA platform enables rapid development of vaccines and therapeutics.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE